4,283 Shares in IQVIA Holdings Inc. $IQV Bought by Eos Management L.P.

Eos Management L.P. bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 4,283 shares of the medical research company’s stock, valued at approximately $965,000.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of IQVIA by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after buying an additional 159,899 shares during the last quarter. Geode Capital Management LLC grew its stake in IQVIA by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock valued at $982,272,000 after acquiring an additional 24,453 shares during the last quarter. Boston Partners increased its holdings in IQVIA by 14.9% during the 4th quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock valued at $923,276,000 after acquiring an additional 530,672 shares in the last quarter. JPMorgan Chase & Co. raised its position in IQVIA by 16.2% during the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock worth $856,468,000 after acquiring an additional 528,753 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in shares of IQVIA by 1.2% in the third quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock valued at $683,323,000 after purchasing an additional 41,643 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Morgan Stanley reiterated an “equal weight” rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a research report on Wednesday. Barclays raised IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a research note on Friday, March 6th. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Sunday, June 14th. Mizuho set a $215.00 price target on IQVIA in a report on Monday, February 23rd. Finally, Evercore restated an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a research report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $222.56.

IQVIA Stock Performance

NYSE:IQV opened at $168.14 on Friday. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The firm has a market cap of $28.06 billion, a PE ratio of 20.84, a P/E/G ratio of 1.44 and a beta of 1.21. The firm has a 50 day simple moving average of $173.63 and a 200-day simple moving average of $191.68. IQVIA Holdings Inc. has a 1-year low of $153.01 and a 1-year high of $247.04.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. IQVIA’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the previous year, the company earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA declared that its board has authorized a stock buyback program on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s management believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.